Navigation Links
BiPar Sciences Expands Phase 2 Clinical Trials of BSI-201, a Novel DNA Repair Inhibitor, in Ovarian Cancer
Date:5/8/2008

- Memorial Sloan-Kettering Cancer Center Investigators to Assess BSI-201

Therapy in BRCA-Negative Ovarian Cancer Patients -

BRISBANE, Calif., May 8 /PRNewswire/ -- BiPar Sciences, Inc. today announced the expansion of Phase 2 clinical trial programs for its lead product, BSI-201, in ovarian cancer. This is the third major clinical trial of BSI-201 that BiPar has launched in the past 6 months, expanding on on-going trials in breast and brain cancer.

The company is evaluating BSI-201, the first poly ADP-ribose polymerase (PARP) inhibitor in its DNA repair portfolio, as a monotherapy for patients whose ovarian cancer is linked to a hereditary genetic defect. Clinicians at Memorial Sloan-Kettering Cancer Center will enroll patients who have a mutation in their BRCA1 or BRCA2 genes.

"We believe BSI-201 holds great promise as a targeted therapy in this difficult-to-treat type of ovarian cancer," said Carol Aghajanian, M.D., co- principal investigator and chief of the gynecologic medical oncology service at Memorial Sloan-Kettering Cancer Center. "BRCA-negative patients are at higher risk of breast and ovarian cancer because BRCA plays a key role in repairing DNA errors that lead to tumor formation."

Ovarian cancer strikes more than 21,000 women a year in the United States and is one of the most common causes of cancer death in women, killing more than 15,000 annually in the United States. Patients with the hereditable BRCA- negative form of the disease account for about 15 percent of the patient population. Women with defective BRCA genes are also at considerably higher risk of breast cancer.

"We have identified a number of important types of cancer where PARP plays a crucial role in tumor growth, and we believe that BRCA-negative ovarian cancer represents another excellent target for BSI-201," said Barry Sherman, M.D., BiPar's Executive Vice President of Development. "We will soon have patients enrolled in four separ
'/>"/>

SOURCE BiPar Sciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. BiPar Sciences Expands Clinical Program for BSI-201, a Novel DNA Repair Inhibitor, in Brain Cancer
2. BiPar Begins Phase 2 Study of Lead PARP Inhibitor in Triple-Negative Breast Cancer Based on Overexpression Biomarker Data
3. BiPar Genomic Biomarker Data Demonstrate Overexpression of PARP-1 Gene in Multiple Cancer Types
4. BiPar Announces Preclinical Data Demonstrating Anti-Tumor Activity With BSI-401, Its Second-Generation PARP Inhibitor
5. BiPar Expands Management Team to Advance Lead PARP Inhibitor Product Candidate Into Phase 2 Trials for Cancer
6. Catalyst Biosciences Selects Drug Development Candidate in Factor VIIa Program for Hemophilia
7. Neurocrine Biosciences Reports First Quarter 2008 Results
8. Caliper Life Sciences Optical Imaging Technology Selected to Aid Tuberculosis Research Efforts by the Texas A&M Health Science Center
9. Human Genome Sciences Completes Enrollment in First of Two Phase 3 Lymphostat-B(R) Trials
10. Edwards Lifesciences Announces First Implants in U.S. Study of Minimally-Invasive Pulmonic Valve
11. Ardea Biosciences Presents Data Demonstrating Favorable Pharmacokinetics and Efficacy for Mitogen-Activated ERK Kinase (MEK) Inhibitors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/8/2008)...ation May Provide New Option for Clinicians Concer...ng an Oral NSAID, TAMPA, Fla., May 8 /PRNewswire-...ng global specialty pharmaceutical company, announ...ek at the American Pain Society annual,meeting dem...harmacokinetic,profile of Alpharma Pharmaceuticals...
(Date:5/7/2008)...udy to Evaluate Preferred Induction Dosing Regimen...n Pharmaceuticals Inc.,(Nasdaq: TRBN ) today anno...ivision of Wyeth (NYSE: WYE ), has commenced pati...TRU-015 in patients with rheumatoid arthritis,(RA)...cals is developing,TRU-015, SBI-087 and other CD20...
(Date:5/7/2008)...y shows how sounds are amplified in the inner ear,... result from genetic mutation or,overdose of drugs... -- St. Jude Children,s,Research Hospital investig...ification mechanism in the cochlea of the ear is c...ammals. The findings will enable better,understand...
(Date:5/7/2008)...ICK, N.J., May 7 /- Johnson... financial analysts on Friday, May 9,at 4:00 p.m. ...Society,s,(APS) annual meeting in Tampa, Fla. Phas... tapentadol immediate release (IR), a novel centra...he first time at APS., A pre-recorded Webcast, wi...
Breaking Medicine Technology:Data Show FLECTOR(R) Patch Yields Significant Pain Reduction for Acute Strains, Sprains and Contusions 2Data Show FLECTOR(R) Patch Yields Significant Pain Reduction for Acute Strains, Sprains and Contusions 3Data Show FLECTOR(R) Patch Yields Significant Pain Reduction for Acute Strains, Sprains and Contusions 4Data Show FLECTOR(R) Patch Yields Significant Pain Reduction for Acute Strains, Sprains and Contusions 5Data Show FLECTOR(R) Patch Yields Significant Pain Reduction for Acute Strains, Sprains and Contusions 6Data Show FLECTOR(R) Patch Yields Significant Pain Reduction for Acute Strains, Sprains and Contusions 7Trubion Announces Initiation of Phase 2b Study of TRU-015 for the Treatment of Rheumatoid Arthritis 2Trubion Announces Initiation of Phase 2b Study of TRU-015 for the Treatment of Rheumatoid Arthritis 3Trubion Announces Initiation of Phase 2b Study of TRU-015 for the Treatment of Rheumatoid Arthritis 4St. Jude Finds 'Dancing' Hair Cells Are Key to Humans' Acute Hearing 2St. Jude Finds 'Dancing' Hair Cells Are Key to Humans' Acute Hearing 3Baxa Corporation Announces Safe Handling and Preparation of Hazardous Drugs Course Offering at its STAR Center Training Facility 14497 1Baxa Corporation Announces Safe Handling and Preparation of Hazardous Drugs Course Offering at its STAR Center Training Facility 14497 2Baxa Corporation Announces Safe Handling and Preparation of Hazardous Drugs Course Offering at its STAR Center Training Facility 14497 3Quiznos Selects Halogen for Fresh Approach to Talent Management 4010 1Quiznos Selects Halogen for Fresh Approach to Talent Management 4010 2Cardium and Tissue Repair Companys Excellarate Candidate for Healing Diabetic Wounds Gains Media Focus in Multiple Regions Across U S 1533 1Cardium and Tissue Repair Companys Excellarate Candidate for Healing Diabetic Wounds Gains Media Focus in Multiple Regions Across U S 1533 2Cardium and Tissue Repair Companys Excellarate Candidate for Healing Diabetic Wounds Gains Media Focus in Multiple Regions Across U S 1533 3Cardium and Tissue Repair Companys Excellarate Candidate for Healing Diabetic Wounds Gains Media Focus in Multiple Regions Across U S 1533 4Cardium and Tissue Repair Companys Excellarate Candidate for Healing Diabetic Wounds Gains Media Focus in Multiple Regions Across U S 1533 5Cardium and Tissue Repair Companys Excellarate Candidate for Healing Diabetic Wounds Gains Media Focus in Multiple Regions Across U S 1533 6A Journal for Karen 3A Author Shares Gift of Love for Sister with Readers Everywhere Touched by Cancer 14490 1A Journal for Karen 3A Author Shares Gift of Love for Sister with Readers Everywhere Touched by Cancer 14490 2
...2007 /PRNewswire-FirstCall/ -- On Wednesday,July ...0:30 p.m.,Central European Time members of Cell Th... a conference call to discuss today,s,announcement...trial,comparing CHOP-R to CPOP-R, in which pixantr...P-R, in first-line treatment of patients,with aggr...
...Automation continues to gain importance in modern ... consolidation, rising demands from clinicians for...tage of licensed medical technologists. Ultimately...omation solutions are better equipped to meet thes...rall laboratory automation (e.g. sample processing...
Other Medicine Technology:Cell Therapeutics, Inc. Management to Discuss Today's Announcement,of Interim Pixantrone Study Results 2Optimizing Quality Control Data Management 2Optimizing Quality Control Data Management 3Optimizing Quality Control Data Management 4Optimizing Quality Control Data Management 5
(Date:5/11/2008)...y 11 /PRNewswire/ -- The winners of today,s Susan ...llows:, 1st Place Overall Winners Male: P...e: Kelly Knickelbein, Pittsburgh, Pa., 19:19, 2n...16:02 Female: Anna Beck, Washington, Pa., 19...e Ban, Pittsburgh, Pa., 16:13 Female: Jessic...
(Date:5/11/2008)...11 /PRNewswire-USNewswire/ -- The situation for ch... of children have been separated,from their famili...n relief,camps, and some are drinking water from p...ted today., The information is contained in a new...s in Myanmar. It details the most urgent needs of ...
(Date:5/11/2008)...the Country on Hand for Unveiling of the New Name ... Organization, CHICAGO, May 11 /PRNewswire/ -- Th...es across the country were present for the unveili... non-profit breast cancer,organization, This year...memorates,its 30th anniversary. In celebration of ...
(Date:5/11/2008)... bought over the counter and safely used at home ,...en you,re doing your spring cleaning, don,t forget...asy way for people with spring allergies, nasal co...relief, says Dr. Melissa Pynnonen, co-director of ...or in the University of Michigan,s department of o...
Breaking Medicine News(10 mins):Health News:16th Annual Komen Pittsburgh Race for the Cure(R) Winners Announced 2Health News:UNICEF REPORT: Desperate Conditions for Children in Camps Without Clean Water as Cyclone Aftermath Worsens 2Health News:UNICEF REPORT: Desperate Conditions for Children in Camps Without Clean Water as Cyclone Aftermath Worsens 3Health News:UNICEF REPORT: Desperate Conditions for Children in Camps Without Clean Water as Cyclone Aftermath Worsens 4Health News:Y-ME Makes Historic Announcement on Mother's Day 2Health News:Y-ME Makes Historic Announcement on Mother's Day 3Health News:Nasal Irrigation Can Help Fight Spring Allergies 2
... packages. So are the twin electroneedles, which i...ents to confirm heart attack episodes. The two ar...penetrating painlessly into the skin. Good thing c... electroneedles, which is targeted at diabetics an...
... Replacement Therapy (HRT) is commonly advocated ...reatment could be associated with increased chance...xpressed. In a study published in British Medical... a cancer developing in woman on HRT is low and no...
...e lower intake of folic acid during the first trim... having babies with low birth weight than anyone e... Tyne, UK, had found that increased levels of foli...ncreased birth weights of newborns, and vice versa...
...identified which could presumably play a major rol...w genes were narrowed down after examination of tu...tion breast cancer cell lines were also studied wh...discovery could provide a basis for new treatment ...
Other Medicine News:Health News:Diabetes and heart attack diagnosis now made simple with twin magic 2Health News:Risk of Breast Cancer Overestimated with Hormone Replacement Therapy(HRT) Treatment 2Health News:Study Links Folic Acid With Increased Birth Weight 2
These units, though small, still offer sufficient output to ensure current is fully adjustable from 0 to 70 mA. Instruction manual, ball electrodes, battery and leads with alligator clips are include
Aaron manufactures two groups of flexible lighting products. The first is available both sterile and non-sterile in three different sizes 5", 10", and 15" (refers to the flexible shaft portion of the
These units, though small, still offer sufficient output to ensure current is fully adjustable from 0 to 70 mA. Instruction manual, ball electrodes, battery and leads with alligator clips are include
Designed to be used for neuromuscular blockage monitoring. Provides for easy placement over the ulnar nerve on a patient's wrist. Dual element permits non-invasive monitoring using a single electrode
Medicine Products: